Florida | 001-35887 | 26-279552 | ||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | file number) | Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
None | n/a | n/a |
MIMEDX GROUP, INC. | ||
Date: April 16, 2020. | By: | /s/ Peter M. Carlson |
Chief Financial Officer |
• | Completed the financial restatement by filing the 2018 Form 10-K on March 17, 2020 |
• | Transitioned our leadership team with the addition of highly qualified and ethical executives |
• | Resolved the matter with the Securities and Exchange Commission |
• | Settled the VA pricing investigation and resolved multiple near-term legal matters |
• | Implemented initiatives for improved effectiveness of our internal control over financial reporting, based on criteria established within the COSO framework |
• | Invested in branding and messaging initiatives focused on building market awareness |
• | Advanced engagement with key industry decision makers, including the Food and Drug Administration (FDA), rebuilding critical relationships with a solution-oriented approach demonstrating category leadership |
1. | Protecting our workforce: To safeguard the health and safety of our employees, we have activated a range of measures including enhanced awareness of Centers for Disease Control (CDC) Guidelines, added cleaning procedures throughout our facilities, and zero-tolerance for the appearance of fever or other potential symptoms and indicators of infectious disease. Certified Medical Assistants (CMAs) are stationed at each entrance to our facilities to screen employee temperatures before entry, and we are providing all onsite employees with cloth face coverings, as recommended by the CDC. For the hourly employees who are critical to our operations, we instituted a temporary wage increase. For our field force, we have developed novel remote tools through our commercial organization to provide continued support and deliver effective customer service to our physician customers. During this difficult economic period, we are choosing to provide continued full employment, implementing a temporary, gradated reduction for our salaried employees, designed to avoid the hardship of further staff reductions or furloughs. This approach allows us to maintain our workforce, address ongoing demand and position the Company to meet accumulated clinical need when facility access is normalized and those attempting to delay treatment seek care. |
2. | Ensuring access to MiMedx products: The needs of the healthcare community demonstrate continued demand for our products - and with support from the hospitals we work with around the nation, we are able to ensure supply and to distribute products where they are most needed. We have refined operational and |
3. | Maintaining business operations: Our sourcing, processing and supply lines remain open and resilient, with strong contingency plans in place for business continuity. We are following the updates provided by federal, state and local public-health sources that set policy, with teams working around the clock to review the advice of health experts, implement updated procedures and advance our quality assurance measures in accordance with latest CDC, FDA and American Association of Tissue Banks guidelines. |
4. | Moving forward: We are progressing in our efforts to become current in financial reporting in the first half of the year, first with the filing of the 2019 Form 10-K, followed by the 2020 Form 10-Q. These filings, along with our proxy statements, enable the Company to schedule and hold the 2019 and 2020 shareholder meetings, both of which are planned for 2020, and allow for increased, timely dialogue and consistent operational and financial updates for our shareholders. Current financial reporting also positions the Company to apply for relisting on the NASDAQ. We continue to dedicate human and capital resources in response to the FDA 483 observations, described within the Company’s 2018 Form 10-K, and to date, have implemented approximately 88% of the committed actions. The entire leadership team is dedicated to providing sustained, visible support for quality initiatives, consistently communicating the Company’s quality standards and expectations to all personnel, and we will continue to implement improvements to further strengthen the Company’s quality systems in line with the recent FDA guidance. |